Giovina Ruberti

Research Areas: Molecular oncology and pathology , Immunology


Monterotondo Scalo – Campus “A.Buzzati Traverso”
+39 06 90091263 (office)
+39 06 90091254 (lab)
giovina.ruberti@cnr.it

Research Focus: Cell signaling, epithelial cancer model systems, Schistosoma mansoni biology, target and drug discovery.

 

My laboratory is active in the fields of cancer biology and Schistosoma mansoni biology. By developing model systems and investigating complex biological processes we aim to identify targets and molecules relevant for unmet medical needs: cancer and schistosomiasis, a neglected tropical disease caused by a parasitic trematode of the genus Schistosoma.

Main lines of research:

  • Role of members of the Death Fold family (Fas receptor, FADD, TRADD, Caspases) in complex biological processes (i.e. apoptosis, cell cycle, cell migration) in physiology and in cancer. Cellular and murine (xenograft) model systems, protein-protein interactions, cell signaling and functional studies are used.
  • Mechanisms of resistance to target therapy in cellular and murine (xenograft) cancer models. Receptor tyrosine kinases in epithelial cancer model systems (i.e.NSCLC) are investigated. Bioinformatics, microarray, mRNA and lncRNA gene expression, in vitro and in vivo functional studies are instrumental for these studies.
  • Biology of the parasitic trematode Schistosoma mansoni (pairing, egg production, metabolism) and identification of novel multi-stage active compounds, and targets.

Education:

07/1979                      High School Diploma, Liceo Scientifico J.F. Kennedy, Rome (60/60)

1979-1985                  Degree in Medicine and Surgery, University of Rome, Sapienza (110/110 cum laude). Tutor Prof. Vincenzo Barnaba

09/1985-01/1987       Research Fellow, Università degli Studi di Roma “La Sapienza”

02/1987                      Visiting Fellow at the German Cancer Research Center (DKFZ) Heidelberg (Laboratory Dr. CM Weyand and Dr. J Goronzy)

02/1987-12/1991       Postdoctoral Fellow Stanford University, Department of Medicine, Division of Immunology, Stanford (CA), USA 

 

Positions:               

12/2001-present        Research Director, National Research Council (CNR), Institute of Biochemistry and Cell Biology (IBBC)-CNR (2019-present), Institute of Cell Biology and Neurobiology (IBCN)-CNR (2010-2019), Institute of Cell Biology (IBC)-CNR (2001-2010)

25/11- 21/12/2010    Acting Director of the IBC-CNR

1/2001-12/2001        Senior Researcher, IBC-CNR     

08/1996-12/2000      Researcher, Institute of Cell Biology (IBC)-CNR

05/1992-08/1996      Research Contract, IBC-CNR, Rome 

 

Honours/Awards:

“Istituto Pasteur-Fondazione Cenci Bolognetti” University of Rome Sapienza Foundation, post-doctoral fellowship abroad (1987-1988)                         

 

Patents:          

USE OF PERHEXILINE, RM2014A000390 16.07.2014; WO/2016/008977; PCT/EP2015/066264 Publication date 21.01.2016; Publication number: US20170157102A1, Abstract: The present invention relates to Perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of a pathology caused by trematodes; Type: Application; Filed: July 16, 2015; Publication date: June 8, 2017; Inventors: Giovina RUBERTI, Cristiana LALLI, Alessandra GUIDI, Alberto BRESCIANI, Nadia GENNARI, Giacomo PAONESSA, Emanuela NIZI; 2020-03-04 abandoned.

Saccoccia F, Brindisi M, Gimmelli R, Relitti N, Guidi A, Saraswati AP, Cavella C, Brogi S, Chemi G, Butini S, Papoff G, Senger J, Herp D, Jung M, Campiani G, Gemma S, Ruberti G. Screening and phenotypical characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) inhibitors as multistage antischistosomal agents. ACS Infect Dis. 2020 Jan 10;6(1):100-113. doi: 10.1021/acsinfecdis.9b00224. Epub 2019 Nov 12.

Papoff G, Presutti D, Lalli C, Bolasco G, Santini S, Manelfi C, Fustaino V, Alemà S, Ruberti G. CASP4 gene silencing in epithelial cancer cells leads to impairment of cell migration, cell-matrix adhesion and tissue invasion. Sci Rep. 2018 Dec 7;8(1):17705. doi: 10.1038/s41598-018-35792-8.

Fustaino V, Presutti D, Colombo T, Cardinali B, Papoff G, Brandi R, Bertolazzi P, Felici G, Ruberti G. Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines. Oncotarget. 2017 Sep 22;8(61): 103340-103363. doi: 10.18632/oncotarget.21132. eCollection 2017 Nov 28.

Guidi A, Lalli C, Perlas E, Bolasco G, Nibbio M, Monteagudo E, Bresciani A, Ruberti G. Discovery and characterization of novel anti-schistosomal properties of the anti-anginal drug, Perhexiline and its impact on Schistosoma mansoni male and female reproductive systems. PLoS Negl Trop Dis. 2016 Aug 12;10(8):e0004928. doi: 10.1371/journal.pntd.0004928. eCollection 2016 Aug.

Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G. MET gene amplification and MET receptor activation are not sufficient to predict efficacy of combined MET and EGFR inhibitors in EGFR TKI-resistant NSCLC cells. PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015.

view all publications

 

  1. Franco A, Barnaba V, Levrero M, Ruberti G, Van Dyke A, Bonavita MS, Balsano F. Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver disease. J Hepatol. 1986;3 Suppl 2: S239-43.
  2. Barnaba V, Levrero M, Franco A, Ruberti G, Musca A, Bonavita MS, Balsano F. Characterization of effector cells in lymphocytotoxicity to autologous hepatocytes in HBsAg-positive and autoimmune chronic active hepatitis (CAH). Liver 1986; 6(1): 45-52.
  3. Barnaba V, Ruberti G, Levrero M, Balsano F. In vitro induction of HBsAg-specific CD8 CD11 human suppressor T cells. Immunology 1987; 62(3): 431-8.
  4. Barnaba V, Levrero M, Ruberti G, van Dyke A, Perrone A, Musca A, Balsano F. In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients. Clin Exp Immunol. 1987; 70(2): 283-8.
  5. Franco A, Barnaba V, Ruberti G, Benvenuto R, Balsano C, Musca A. Liver-derived T cell clones in autoimmune chronic active hepatitis: accessory cell function of hepatocytes expressing class II major histocompatibility complex molecules. Clin Immunol Immunopathol. 1990; 54(3):382-94.
  6. Puré E, K Inaba, MT Crowley, L Tardelli, MD Witmer-Pack, G Ruberti, CG Fathman and RM Steinman. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. J. Exp. Med. 1990; 172: 1459-1469.
  7. McClure GC, G Ruberti, CG Fathman, HA Herlich and AB Begovich. DRB1*Ly10- a new DRB1 allele and its haplotypic association. Immunogenetics 1990; 32: 214-217.
  8. Ruberti G, AB Begovich, AC Steere, W Klitz, HA Erlich and CG Fathman. Molecular analysis of the role of the HLA class II genes, DRB1, DQA1, DQB1 and DPB1 in susceptibility to Lyme Arthritis. Hum Immunol. 1991; 31: 20-27.
  9. Ruberti G, A Gaur, CG Fathman and AM Livingstone. The T cell receptor repertoire influences Vβ element usage in response to myoglobin. J Exp Med. 1991; 174: 83-92.
  10. Ruberti G, AM Livingstone, JS Danska, A Gaur, and CG Fathman. Analysis of the ternary complex of antigen, MHC and T cell receptor: the influence of the T cell receptor Vβ repertoire on the Vβ gene element usage. Res Immunol. 1991; 142: 491-493.
  11. Ruberti G, KS Sellins, CM Hill, RN Germain, CG Fathman and AM Livingstone. Presentation of antigens by mixed isotype class II molecules in normal H-2d mice. J Exp Med. 1992; 175: 157-162.
  12. Gaur A, Ruberti G, Haspel R, Mayer JP, Fathman CG. Requirement for CD8+ cells in T cell receptor peptide-induced clonal unresponsiveness. Science 1993; 259(5091):91-4.
  13. Ruberti G, V Paragas, K Dewey and CG Fathman. Selection for amino acid sequence and Jβ element usage in β chain of DBA/2Vβa and DBA/2Vβb derived myoglobin specific T cell clones. J Immunol. 1993; 151: 6185-6194.
  14. Fiucci G, Ruberti G. Detection of polymorphisms within the FAS cDNA gene sequence by GC clampdenaturing gradient gel electrophoresis. Immunogenetics 1994; 39 (6): 437-439.
  15. Cascino I, Fiucc, G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154 (6): 2706-2713.
  16. Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: Sequential involvement of phosphatidylcholine specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal EMBO J 1995; 14 (23): 5859-5868.
  17. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996; 156 (1): 13-17.
  18. Ruberti G, Cascino I, Papoff G, Eramo A. Fas splicing variants and their effect on apoptosis. Adv Exp Med Biol. 1996; 406:125-34. Review.
  19. Cascino I, Papoff G, Eramo A, Ruberti G. Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci. 1996; 1:d12-8. Review.
  20. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156 (12): 4622-4630.
  21. Baiocchi RA, Khatri VP, Lindemann MJ, Ros, ME, Papoff G, Caprio AJ, Caprio TV, Fenstermaker R, Ruberti G, Bernstein, ZP, Caligiuri, MA. Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. Blood 1997; 90 (5): 1737-1746.
  22. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi, R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto’sthyroiditis. Science 1997; 275 (5302): 960-963.
  23. Signore A, Annovazzi A, Procaccini E, Beales PE, Spencer J, Testi R, Ruberti G. CD95 and CD95- ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice. Diabetologia 1997; 40(12):1476-9.
  24. Häusler P, Papoff G, Eramo A, Reif K, Cantrell DA, Ruberti G. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur. J. of Immunol 1998; 28 (1): 57-69.
  25. Cascino I, Ballerini C, Audino S, Rombolà G, Massacesi L, Colombo G, Scorza Smeraldi R, d’Alfonso S, Momigliano Richiardi P, Tosi R, Ruberti G. Fas gene polymorphisms are not associated with systemic lupus erythematosus, multiple sclerosis and HIV infection. Dis Markers 1998, 13(4): 221-5.
  26. Ruberti G, Signore A. CD95 ligand expression on alpha cells: protection or killing? Diabetes Metab Rev 1998; 14(2): 191-2.
  27. Prasad NKA, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri, SV. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161 (7): 3781-3790.
  28. Signore A, Annovazzi A, Gradini R, Liddi R, Ruberti G. Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes. Diabetes Metab Rev 1998; 14(3):197-206. Review.
  29. Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D’Alessandro N, Papoff G, Ruberti G, Rausa L. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ. 1998; 5(9): 735-42.
  30. Papoff G, Hausler P, Eramo A, Pagano MG, Di Leve G, Signore A, Ruberti G. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999; 274 (53): 38241-38250.
  31. Signore A, Annovazzi A, Giacalone P, Beales PE, Valorani MG, Vestri AR, Ruberti G, Manfrini, S, Pozzilli P, Bulfone-Paus S. Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL-15-murine IgG2b in NOD mice. Diabetes Metab Res Rev. 2003; 19 (6): 464-468.
  32. Meli M, Tolomeo M, D’Alessandro N, Grimaudo S, Notarbartolo M, Papoff G, Ruberti G, Rausa L, Dusonchet L. Resistance to Gemcitabine in a Lymphoma Cell Line Resistant to Fas- mediated Apoptosis. Anticancer Res 2004; 24 (2 B): 851-857.
  33. Varambally S, Bar-Dayan Y, Bayry J, Lacroix-Desmazes S, Horn M, Sorel M, Bar-Dayan Y, Ruberti G, Kazatchkine MD, Kaveri SV. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol. 2004; 16 (3): 517-524.
  34. Malquori L, Carsetti L, Ruberti G. The 3′-UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency. Biochim Biophys Acta 2008; 1779 (1): 60-5.
  35. Papoff G, Trivieri N, Crielesi R, Ruberti F, Marsilio S, Ruberti G. FADD-calmodulin interaction: a novel player in cell cycle regulation Biochim Biophys Acta 2010; 1803(8): 898-911.
  36. Papoff G, Trivieri N, Marsilio S, Crielesi R, Lalli C, Castellani L, Balog EM, Ruberti G. N- Terminal and C-Terminal Domains of Calmodulin Mediate FADD and TRADD Interaction. PLoS One. 2015 Feb 2;10(2):e0116251. doi: 10.1371/journal.pone.0116251. eCollection 2015.
  37. Lalli C, Guidi A, Gennari N, Altamura S, Bresciani A, Ruberti G. Development and validation of a     luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni. PLoS Negl Trop Dis. 2015 Jan 30;9(1):e0003484. doi: 10.1371/journal.pntd.0003484. eCollection 2015 Jan.
  38. Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G. MET gene amplification and MET receptor activation are not sufficient to predict efficacy of   combined MET and EGFR inhibitors in EGFR TKI-resistant NSCLC Cells. PLoS One. 2015 Nov     18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015.
  39. Guidi A, Lalli C, Perlas E, Bolasco G, Nibbio M, Monteagudo E, Bresciani A, Ruberti G. Discovery and characterization of novel anti-schistosomal properties of the anti-anginal drug, Perhexiline and its impact on Schistosoma mansoni male and female reproductive systems. PLoS Negl Trop Dis. 2016 Aug 12;10(8):e0004928. doi: 10.1371/journal.pntd.0004928. eCollection 2016 Aug.
  40. Guidi A, Lalli C, Gimmelli R, Nizi E, Andreini M, Gennari N, Saccoccia F, Harper S, Bresciani A, Ruberti G. Discovery by organism based high-throughput screening of new multi-stage compounds     affecting Schistosoma mansoni viability, egg formation and production. PLoS Negl Trop Dis. 2017 Oct 6;11(10):e0005994. doi10.1371/journal.pntd.0005994. eCollection 2017 Oct.
  41. Fustaino V, Presutti D, Colombo T, Cardinali B, Papoff G, Brandi R, Bertolazzi P, Felici G and Ruberti G. Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes           associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines. Oncotarget J. 2017 Sep 22;8(61):103340-103363. doi: 10.18632/oncotarget.21132. eCollection 2017 Nov 28.
  42. Compagnone M, Gatti V, Presutti D, Ruberti G, Fierro C, Markert EK, Vousden KH, Zhou H, Mauriello A, Anemone L, Bongiorno-Borbone L, Melino G, Peschiaroli A. ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis. Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13254-13259. doi: 10.1073/pnas.1711777114. Epub 2017 Nov 21.
  43. Presutti D, Ceccarelli M, Micheli L, Papoff G, Santini S, Samperna S, Lalli C, Zentilin L, Ruberti G, Tirone F. Tis21-gene therapy inhibits medulloblastoma growth in a murine allograft model. PLoS One 2018 Mar 14;13(3):e0194206. doi: 10.1371/journal.pone.0194206. eCollection 2018.
  44. Papoff G, Presutti D, Lalli C, Bolasco G, Santini S, Manelfi C, Fustaino V, Alemà S, Ruberti G. CASP4 gene silencing in epithelial cancer cells leads to impairment of cell migration, cell-matrix adhesion and tissue invasion. Sci Rep. 2018 Dec 7;8(1):17705. doi: 10.1038/s41598-018-35792-8.
  45. Guidi A, Saccoccia F, Gennari N, Gimmelli R, Nizi E, Lalli C, Paonessa G, Papoff G, Bresciani A, Ruberti G. Identification of novel multi-stage histone deacetylase (HDAC) inhibitors that impair Schistosoma mansoni viability and egg production. Parasit Vectors 2018 Dec 27;11(1):668. doi: 10.1186/s13071-018-3268-8.12.
  46. Casertano M, Imperatore C, Luciano P, Aiello A, Putra MY, Gimmelli R, Ruberti G, Menna M. Chemical investigation of the Indonesian Tunicate Polycarpa aurata and evaluation of the effects against Schistosoma mansoni of the novel alkaloids Polyaurines A and B. Mar Drugs 2019 May 10;17(5). pii: E278. doi: 10.3390/md17050278.
  47. Saccoccia F, Brindisi M, Gimmelli R, Relitti N, Guidi A, Saraswati AP, Cavella C, Brogi S, Chemi G, Butini S, Papoff G, Senger J, Herp D, Jung M, Campiani G, Gemma S, Ruberti G. Screening and phenotypical characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) inhibitors as multistage antischistosomal agents. ACS Infect Dis. 2020 Jan 10;6(1):100-113. doi: 10.1021/acsinfecdis.9b00224. Epub 2019 Nov 12.
  1. Gimmelli R, Persico M, Imperatore C, Saccoccia F, Guidi A, Casertano M, Luciano P, Pietrantoni A, Bertuccini L, Paladino A, Papoff G, Menna M, Fattorusso C, Ruberti G. Thiazinoquinones as new promising multistage schistosomicidal compounds impacting Schistosoma mansoni and egg viability. ACS Infect Dis. 2020 Jan 10;6(1):124-137. doi: 10.1021/acsinfecdis.9b00252. Epub 2019 Nov 27.
  2. Imperatore C, Gimmelli R, Persico M, Casertano M, Guidi A, Saccoccia F, Ruberti G, Luciano P, Aiello A, Parapini S, Avunduk S, Basilico N, Fattorusso C, Menna M. Investigating the antiparasitic potential of the marine sesquiterpene Avarone, its reduced form Avarol, and the novel semisynthetic thiazinoquinone analogue Thiazoavarone. Mar Drugs. 2020 Feb 14;18(2). pii: E112. doi: 10.3390/md18020112.

 

Researchers:

Postdoctoral Fellows

 

PhD student:

 

 

 

 

Principal Investigator (PI), if not otherwise indicated of the following Research Projects:

 

1993-1995 VI-VII-VIII AIDS Research Project (National Institute of Health, ISS)“Polymorphisms and expression analysis of the pro-apoptotic Fas gene in healthy and HIV positive individuals”

 

1994-1997 Human Capital and Mobility European Commission “Signal transduction mechanisms that control the activation, growth and apoptosis of T lymphocytes” (EC HCM Network CHRX-CT94–0537, coordinator Prof. Doreen A Cantrell, Imperial Cancer Research Fund (ICRF) UK)

 

1995-1997 AIRC (Italian Association for Cancer Research) “Regulation of Fas-mediated apoptosis”

 

1996-1997   CNR Strategic Project “Cell cycle and apoptosis” – IBC-CNR unit: “Modulation of Fas and FasL in physiologic and patological conditions”

 

1996 IX AIDS Project (ISS) “Role of Fas in T lynphocyte depletion in HIV infection: Fas variants and identification of genes involved in apoptotic signal transduction pathways”

 

1996-1998 Telethon “Role of Fas and Fas Ligand in the pathogenesis of type I diabetes”.

 

1997-1999   Biomed 2 EC “Surface receptor-induced apoptosis in transformed cells: defining the molecular events involved in TNF-R1 and Fas apoptotic signaling” (European Biomed Program Grant BMH4-CT96-0300, coordinator Prof. Roberto Testi, University of Tor Vergata, Rome, Italy)

 

1997-1998 AIDS (ISS) “Regulation of Fas-mediated apoptosis. Strategies to interfere with increased susceptibility to apoptosis in HIV infection”

 

1998-2000 AIRC “Identification and characterization of mechanisms that regulate the CD95 induced apoptotic signal”

 

1998-2000 CNR Progetto Finalizzato Biotecnlogie “Regulation of Fas-mediated apoptosis. Strategies to interfere with apoptotic signaling”

 

1998-2000 Training and Mobibility European Commission “Regulation of apoptosis in tissue homeostasis and cancer: role of TNF-R1 and Fas” (coordinator Prof. Peter Daniel, Humboldt-Universität zu Berlin; Germany)

 

2000-2001 CNR Strategic Project “Post-genomics technologies” – IBC-CNR unit: “Identification of novel genes that modulate the apoptotic process”

 

2001 AIRC “Trafficking and compartmentalization analysis of apoptotic elements regulating Fas and FADD signaling”

 

2002-2003 MIUR-CNR Project Functional genomics–Function of genes at the cellular and organism level. The IBC-CNR unit coordinated also research groups of the University of Rome Tor Vergata and of the University of Udine “COntrolling Modulated Elements Transducing Apoptosis (COMETA)”

 

2002 Juvenile Diabetes Research Foundation, Innovative USA Grant “Role of T1DM associated CTLA-4 Polymorphisms on protein Trafficking and Compartmentalization”

 

2005 CNR-curiosity driven Project (Ricerca a tema libero) “FADD and TRADD non apoptotic functions”

 

2005-2007 Juvenile Diabetes Research Foundation-Telethon. “IDDM12 Locus Analysis in T1DM: Identification and Characterization of Functional Polymorphisms”

 

2011-2013 Project “Innovative drugs and biotechnology networks of Quality” (FaReBio di Qualità) supported by a grant from the Italian Ministry of Economics and Finances to the CNR. IBCN-CNR Unit: “Laboratory node for Innovative drugs discovery: cellular and murine models and functional studies. The IBCN-CNR unit coordinated also research groups of IBBE-CNR and IBIM-CNR.

 

2012 Project CNR-CNCCS “Collezione di composti chimici ed attività di screening”, Public-private project in collaboration with IRBM Science Park srl.

 

2012-2013 MIUR-PRIN2009 “Resistance to target therapy and ErbB receptors inhibitors” (Coordinator Prof. Silvia Giordano, Responsbile CNR-Unit Dr. Stefano Alemà)

 

2012-2020 Project CNR-CNCCS – Rare, Neglected and Poverty Related Diseases – Schistodiscovery Project. Schistosomiasis -Innovative drugs discovery, in collaboration with IRBM Science Park

 

2013-2016 MIUR-CNR Progetto premiale “Medicina personalizzata” BBT (Biomarcatori, Bersagli, Tumori) – Identificazione di biomarcatori e bersagli in tumori umani polmonari farmaco-resistenti ed in tumori neuroendocrini per approcci diagnostici e terapeutici innovativi.

 

2014-2015 CNR-Regione Lazio Sviluppo piattaforme di drug discovery per target epigenetici Public-private project in collaboration with IRBM Science Park srl.“Schistosomiasis: identification of epigenetic targets”

 

2016-2019 MIUR-PRIN 2015 Towards multi-stage drugs to fight poverty related and neglected parasitic diseases: synthetic and natural compounds directed against Leishmania, Plasmodium and Schistosoma life stages and assessment of their mechanisms of action (Coordinator Prof. Giuseppe Campiani, University of Siena)

 

2018-2020 “LIFE 2020” – POR FESR LAZIO 2014-2020, REGIONE LAZIO. PISTA (PI3k for Solid Tumor therapy) (PI CNR Uniti; Coordinator, Monica Binaschi; Menarini Ricerche).